Hong Kong Science and Technology Parks Corporation, known as HKSTP, made its first appearance at MEDICA 2026 in Düsseldorf, Germany, from 16 to 19 November, leading a delegation of 22 companies from its park and university partners. The move signals an effort to link Hong Kong's life and health technology sector with European buyers, regulators and research networks.
The delegation was joined by the Hong Kong Trade Development Council and the Hong Kong MedTech Association. HKSTP says it supports more than 400 life and health technology companies, and the trade fair gave its members a platform to present products and pursue partnerships abroad.
Several memoranda of understanding were signed during the event. HKSTP agreed with Medical Valley EMN to work on market access, business matching and clinical research, and with Kalms Consulting on regulatory readiness and support for commercialisation in Europe. Orange Biotech also signed an agreement with Hungary's CorLab to develop CRISPR-based point-of-care diagnostics.
Other deals involved Pushkang Biotechnology, which agreed with Egypt's Keen Diagnostic Partners to roll out its analysers, and AusMed Global, which began a European soft launch of a portable breath ketone monitor that carries CE marking. Dymind, meanwhile, introduced an upgraded CE-marked haematology analyser, the DH-8000, aimed at large laboratories.
The event also cited a projection that China's medical devices market could reach USD 82 billion by 2032, a figure that underlines the commercial stakes for firms looking beyond their home markets. Park companies have recently won awards at BioJapan 2026 and at a competition in Washington.
The outcomes of these memoranda and commercial arrangements have not yet been proven, and no revenue figures have been disclosed. Whether the agreements translate into sales and clinical partnerships will become clearer in the months ahead.
Credit. Based on reporting by Devki Yadav for Newspatrolling.com. Is this your work? Write to us.
22





